Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Teva
Cantor Fitzgerald
Julphar
Chubb
Chinese Patent Office
Medtronic
Moodys
Harvard Business School

Generated: December 12, 2017

DrugPatentWatch Database Preview

VIZAMYL Drug Profile

« Back to Dashboard

When do Vizamyl patents expire, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-six patent family members in twenty-three countries and eighteen supplementary protection certificates in twelve countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.

Summary for VIZAMYL

Drug patent expirations by year for VIZAMYL

Pharmacology for VIZAMYL

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIZAMYL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,854,920Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
9,808,541Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
8,911,707Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIZAMYL

Country Document Number Estimated Expiration
Luxembourg92634► Subscribe
Australia2008202626► Subscribe
Japan2010536931► Subscribe
Cyprus1113311► Subscribe
Japan2004506723► Subscribe
Israel203316► Subscribe
Japan5367708► Subscribe
Hong Kong1146710► Subscribe
Australia2004221897► Subscribe
Russian Federation2475267► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIZAMYL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00723Netherlands► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
00724Netherlands► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
634Luxembourg► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
C0005France► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
15/004Ireland► SubscribePRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
90009-5Sweden► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
15/005Ireland► SubscribePRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2015 00009Denmark► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822
15006Norway► SubscribePRODUCT NAME: VIZAMYL; REG. NO/DATE: EU/1/14/941 20140822
2015000017Germany► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/14/941 20140822
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Covington
Accenture
Dow
AstraZeneca
Johnson and Johnson
Argus Health
Chubb
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot